1,089 research outputs found
Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].
No full text2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association
No full text2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association
No full text2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes
No full textCoronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1
ESC Committee for Practice Guidelines 2002-2004; ESC Committee for Practice Guidelines 2000-2002; European Society of Cardiology 2002-2004. Medical practice guidelines. Separating science from economics.
No full textOver the past twenty years, practice guidelines have become an increasingly popular tool for synthesis of clinical information. The objectives of guidelines are to enhance the appropriateness of practice, improve quality of cardiovascular care, lead to better patient outcomes, improve cost-effectiveness, help authorities to decide on the approval of drugs and devices and identify areas of research needed. Guidelines may also be used as quality measurement for the health insurance.
This article summarizes the ESC policy on the management of guidelines on cardiovascular disorsers
Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))
No full textIn row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'
Managing atrial fibrillation in the global community: The European perspective.
No full textAtrial fibrillation is a common, global problem, with great personal, economic and social burdens. As populations age it increases in prevalence and becomes another condition that requires careful chronic management to ensure its effects are minimised. Assessment of the risk of stroke using well established risk prediction models is being aided by modern computerised databases and the choice
of drugs to prevent strokes is ever expanding to try and improve the major cause of morbidity in AF. In addition, newer drugs for controlling rhythm are available and guidelines are constantly changing to reflect this. As well as medications, modern techniques of electrophysiology are becoming more widely embraced worldwide to provide more targeted treatment for the underlying pathophysiology. In this review we consider these factors to concisely describe how AF can be successfully managed
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010)
No full textGuidelines summarize and evaluate all currently available evidence ona
particular issuewith the aimof assisting physicians in selecting the best
management strategies for an individual patient, suffering from a given
condition, taking into account the impact on outcome, as well as the
risk–benefit ratio of particular diagnostic or therapeutic means.
Guidelines are no substitutes for textbooks, and their legal implications
have been discussed previously. Guidelines and recommendations
should help physicians to make decisions in their daily practice.
However, the ultimate judgement regarding the care of an individual
patient must be made by his/her responsible physician(s).
A large number of Guidelines have been issued in recent years by
the European Society of Cardiology (ESC) as well as by other
societies and organizations. Because of the impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user.
The recommendations for formulating and issuing ESC Guidelines
can be found on the ESC Web Site (http://www.escardio.org/
guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx).
Members of this Task Force were selected by the ESC to represent
all physicians involved with the medical care of patients in
this pathology. In brief, experts in the field are selected and undertake
a comprehensive review of the published evidence for management
and/or prevention of a given condition. A critical evaluation of
diagnostic and therapeutic procedures is performed, including
assessment of the risk–benefit ratio. Estimates of expected health
outcomes for larger populations are included, where data exist.
The level of evidence and the strength of recommendation of particular
treatment options are weighed and graded according to predefined
scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels have provided
disclosure statements of all relationships they may have which
might be perceived as real or potential sources of conflicts of interest.
These disclosure forms have been compiled into one file and can
be found on the ESCWeb Site (http://www.escardio.org/guidelines).
Any changes in disclosures of interest that arise during the writing
period must be notified to the ESC. The Task Force report received
its entire financial support from the ESC without any involvement
from the pharmaceutical, device, or surgical industry.
The ESC Committee for Practice Guidelines (CPG) supervises
and coordinates the preparation of new Guidelines produced by
Task Forces, expert groups, or consensus panels. The Committee
is also responsible for the endorsement process of these Guidelines.The finalized document has been approved by all the experts
involved in the Task Force, and was submitted to outside specialists
for review. The document was revised, and finally approved by and
subsequently published in the European Heart Journal.
After publication, dissemination of the message is of paramount
importance. Pocket-sized versions and personal digital assistant
(PDA) downloadable versions are useful at the point of care.
Some surveys have shown that the intended end-users are sometimes
unaware of the existence of guidelines, or simply do not translate
them into practice, so this is why implementation programmes
for new guidelines form an important component of the dissemination
of knowledge. Meetings are organized by the ESC, and directed
towards its member National Societies and key opinion leaders in
Europe. Implementation meetings can also be undertaken at national
levels, once the guidelines have been endorsed by the ESC member
societies, and translated into the national language. Implementation
programmes are needed because it has been shown that the
outcome of disease may be favourably influenced by the thorough
application of clinical recommendations.
Thus, the task of writing guidelines covers not only the integration
of the most recent research, but also the creation of educational
tools and implementation programmes for the recommendations.
The loop between clinical research, writing of guidelines, and implementing
them in clinical practice can then only be completed if
surveys and registries are performed to verify that real-life daily practice
is in keeping with what is recommended in the guidelines. Such
surveys and registries also make it possible to evaluate the impact
of implementation of the guidelines on patient outcomes. The guidelines
do not, however, override the individual responsibility of health
professionals to make appropriate decisions in the circumstances of
the individual patients, in consultation with that patient, and where
appropriate and necessary the patient’s guardian or carer. It is also
the health professional’s responsibility to verify the rules and regulations
applicable to drugs and devices at the time of prescription
ESC Committee for Practice Guidelines: providing knowledge to everyday clinical practice.
No full textACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and theHeart Rhythm Society
No full textAtrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance, increasing in prevalence with age. AF is often associated with structural heart disease, although a substantial proportion of patients with AF have no detectable heart disease. Hemodynamic impairment and thromboembolic events related to AF result in significant morbidity, mortality, and cost. Accordingly, the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) created a committee to establish guidelines for optimum management of this frequent and complex arrhythmia
- …
